Description

PAZOM 20 MG

Indications

PAZOM 20 MG, containing the active ingredient Pazopanib, is primarily indicated for the treatment of advanced renal cell carcinoma (RCC) and soft tissue sarcoma (STS) in patients who have received prior chemotherapy. It is utilized as a targeted therapy aimed at inhibiting tumor growth and progression by interfering with specific molecular pathways associated with cancer cell proliferation and survival.

Mechanism of Action

Pazopanib is a multi-targeted tyrosine kinase inhibitor that works by blocking the action of certain proteins involved in the growth and spread of cancer cells. Specifically, it inhibits vascular endothelial growth factor receptors (VEGFR), platelet-derived growth factor receptors (PDGFR), and c-KIT. By inhibiting these receptors, PAZOM disrupts the signaling pathways that promote angiogenesis (the formation of new blood vessels) and tumor growth, ultimately leading to reduced tumor size and improved patient outcomes.

Pharmacological Properties

The pharmacokinetics of PAZOM indicate that it is well absorbed following oral administration, with peak plasma concentrations occurring approximately 3 to 6 hours post-dose. The drug exhibits a volume of distribution of approximately 7.2 L/kg and is extensively metabolized in the liver, primarily by cytochrome P450 3A4. The elimination half-life of Pazopanib is approximately 30 hours, allowing for once-daily dosing. It is important to note that food intake can affect the absorption of PAZOM, with a high-fat meal increasing its bioavailability.

Contraindications

PAZOM 20 MG is contraindicated in patients with a known hypersensitivity to Pazopanib or any of its excipients. Additionally, it should not be used in patients with severe hepatic impairment or those who are pregnant or breastfeeding due to potential risks to the fetus or infant. Caution is advised in patients with a history of cardiac conditions, as Pazopanib may prolong the QT interval and increase the risk of arrhythmias.

Side Effects

Common side effects associated with PAZOM include fatigue, diarrhea, hypertension, nausea, vomiting, and liver enzyme abnormalities. Serious adverse effects may include hepatotoxicity, cardiac events such as myocardial infarction, and gastrointestinal perforation. Regular monitoring of liver function tests and blood pressure is recommended during treatment. Patients should be educated on recognizing signs of serious side effects and advised to seek medical attention if they experience symptoms such as chest pain, severe abdominal pain, or jaundice.

Dosage and Administration

The recommended dosage of PAZOM is 800 mg taken orally once daily, with or without food. It is essential to swallow the tablets whole and not to crush or chew them. In cases of hepatic impairment, dose adjustments may be necessary, and close monitoring is recommended. If a dose is missed, patients should take it as soon as they remember on the same day; however, if it is close to the time of the next dose, the missed dose should be skipped. Patients should not take two doses at the same time to make up for a missed dose.

Interactions

Pazopanib is primarily metabolized by CYP3A4, and concomitant use of strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) can increase Pazopanib levels, leading to an increased risk of adverse effects. Conversely, strong CYP3A4 inducers (e.g., rifampicin, St. John’s Wort) may decrease the efficacy of PAZOM by reducing its plasma concentration. Patients should inform their healthcare provider about all medications, supplements, and herbal products they are taking to avoid potential interactions.

Precautions

Before initiating treatment with PAZOM, a thorough assessment of the patient’s medical history is essential. Patients with pre-existing hypertension should have their blood pressure controlled prior to starting therapy, as Pazopanib can exacerbate hypertension. Regular monitoring of blood pressure and liver function tests is crucial during treatment. Patients should be advised to maintain adequate hydration and report any signs of dehydration or gastrointestinal symptoms. Additionally, caution should be exercised in patients with a history of thromboembolic events, as Pazopanib may increase the risk of thrombosis.

Clinical Studies

Clinical studies have demonstrated the efficacy of PAZOM in patients with advanced RCC and STS. In a pivotal Phase III trial for RCC, Pazopanib showed a significant improvement in progression-free survival compared to placebo, with a median progression-free survival of 11.1 months versus 2.8 months for the placebo group. In patients with STS, the drug also exhibited a favorable response rate, with a manageable safety profile. These findings support the use of PAZOM as a valuable therapeutic option in the management of advanced malignancies.

Conclusion

PAZOM 20 MG represents a significant advancement in the treatment of advanced renal cell carcinoma and soft tissue sarcoma. With its targeted mechanism of action and established efficacy, it provides an important option for patients with these challenging malignancies. However, careful consideration of contraindications, potential side effects, and drug interactions is essential to optimize treatment outcomes and ensure patient safety. Ongoing monitoring and patient education are critical components of the treatment plan to manage any adverse effects effectively.